Technische Universität München

American Heart Association. Scientific Sessions

Ten-year Clinical Outcomes From A Randomized Trial Of Polymer-free Sirolimus- And Probucol-eluting Stents Versus Permanent Polymer Zotarolimus-eluting Stents In Patients With Coronary Artery Disease

Sebastian Kufner[1], *Max Ernst*[1], *Salvatore Cassese*[1], *Michael Joner*[1], *Tareq Ibrahim*[2], *Tobias Koppara*[2], *Erion Xhepa*[1], *Tobias Koch*[1], *Katharina Mayer*[1], *Heribert Schunkert*[1], *Karl Ludwig Laugwitz*[2], *Robert A Byrne*[1], *Adnan Kastrati*[1]

From: [1]*Deutsches Herzzentrum München, Munich, Germany*

[2]*1st medizinische Klinik Klinikum rechts der Isar, Technische Universität München, Munich, Germany*

on behalf of

The **I**ntracoronary **S**tenting and **A**ngiographic **R**esults:
Test **E**fficacy of Sirolimus- and Probucol- and Zotarolimus- Eluting **St**ents (**ISAR-TEST 5**) Investigators

ISAR TEST 5 Main Result: Primary Endpoint (DOCE) at 10 Years

American Heart Association. Scientific Sessions



Cumulative incidence of POCE all cause death, any MI or any revascularisation



Cumulative incidence of definite/propable stent-thrombosis



ISAR TEST 5

Clinical Results at 10 years

American Heart Association. Scientific Sessions

	PF-SES (n = 2002)	PP-ZES (n = 1000)	Hazard ratio (95% CI)	P-value
Device-oriented outcomes				
DOCE	**765 (43.8)**	**370 (43.0)**	**1.01 (0.89-1.14)**	**0.90**
Cardiac death	438 (26.7)	217 (26.9)	0.99 (0.84-1.16)	0.86
MI related to target vessel	69 (3.8)	41 (4.4)	0.83 (0.57-1.23)	0.35
Target lesion revascularization	371 (21.9)	175 (20.6)	1.04 (0.87-1.25)	0.67
Patient-oriented outcomes				
POCE	**1250 (65.5)**	**647 (67.5)**	**0.93 (0.85-1.03)**	**0.15**
All-cause death	637 (35.0)	343 (37.3)	0.91 (0.80-1.04)	0.16
Any MI	103 (5.7)	52 (5.8)	0.98 (0.70-1.37)	0.91
Any revascularization	811 (45.0)	412 (46.6)	0.95 (0.85-1.07)	0.42
Stent thrombosis				
Definite or probable	**29 (1.6)**	**17 (1.9)**	**0.85 (0.46-1.54)**	**0.58**

Technische Universität München

Conclusion

- In this unique long-term analysis out to 10 years, there were no measurable differences in outcomes between patients treated with a polymer-free sirolimus- and probucol-eluting stent and those treated with a new generation durable polymer-based zotarolimus-eluting stent.

- Although, the incidence of stent thrombosis was low in both groups high cumulative clinical event rates were observed during 10-year follow-up.